Cowen and Company reiterated their buy rating on shares of Stemline Therapeutics Inc (NASDAQ:STML) in a report released on Thursday.
“STML announced that it has completed enrollment of SL-401’s pivotal study in BPDCN.”,” Cowen and Company’s analyst wrote.
STML has been the topic of several other research reports. HC Wainwright restated a buy rating and issued a $34.00 target price on shares of Stemline Therapeutics in a research note on Monday. Roth Capital restated a buy rating and issued a $32.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 7th. Wedbush restated an outperform rating and issued a $15.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, December 6th. Ladenburg Thalmann Financial Services set a $41.00 target price on Stemline Therapeutics and gave the company a buy rating in a research note on Monday. Finally, Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $24.33.
Stemline Therapeutics (NASDAQ:STML) traded up 0.59% during midday trading on Thursday, hitting $8.55. The stock had a trading volume of 42,781 shares. The firm’s market capitalization is $153.48 million. The firm has a 50-day moving average price of $7.79 and a 200-day moving average price of $10.60. Stemline Therapeutics has a 1-year low of $4.06 and a 1-year high of $14.60.
In other Stemline Therapeutics news, insider David Gionco sold 6,486 shares of the business’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $45,337.14. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. Insiders have sold a total of 65,356 shares of company stock worth $531,879 in the last ninety days. Insiders own 16.70% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in Stemline Therapeutics during the third quarter valued at $400,000. State Treasurer State of Michigan bought a new position in Stemline Therapeutics during the third quarter valued at $217,000. Oak Ridge Investments LLC raised its position in Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 2,663 shares during the period. Columbus Circle Investors bought a new position in Stemline Therapeutics during the third quarter valued at $1,577,000. Finally, Baker BROS. Advisors LP bought a new position in Stemline Therapeutics during the third quarter valued at $3,612,000. 37.76% of the stock is currently owned by hedge funds and other institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.